Endocrine and Metabolic Manifestations of Invasive Fungal Infections and Systemic Antifungal Treatment

[Guest guest]

Second article in the current issue of Mayo Clinic Proceedings.($10 for complete

article, or wait 6 months and it's free)

.................................................................................\

...................

MICHAIL S. LIONAKIS, MD, SCD; GEORGE SAMONIS, MD; DIMITRIOS P. KONTOYIANNIS, MD,

MS, SCD 

Address correspondence to Dimitrios P. Kontoyiannis, MD, MS, ScD, Department of

Infectious Diseases, Infection Control and Employee Health, Unit 402, The

University of Texas M. D. Cancer Center, 1515 Holcombe Blvd, Houston,

TX 77030 (dkontoyi@...).

 

Systemic fungal infections are increasingly reported in immunocompromised

patients with hematological malignancies, recipients of bone marrow and solid

organ allografts, and patients with AIDS. Mycoses may infiltrate endocrine

organs and adversely affect their function or produce metabolic complications,

such as hypopituitarism, hyperthyroidism or hypothyroidism, pancreatitis,

hypoadrenalism, hypogonadism, hypernatremia or hyponatremia, and hypercalcemia.

Antifungal agents used for prophylaxis and/or treatment of mycoses also have

adverse endocrine and metabolic effects, including hypoadrenalism, hypogonadism,

hypoglycemia, dyslipidemia, hypernatremia, hypocalcemia, hyperphosphatemia,

hyperkalemia or hypokalemia, and hypomagnesemia. Herein, we review how mycoses

and conventional systemic antifungal treatment can affect the endocrine system

and cause metabolic abnormalities. If clinicians are equipped with better

knowledge of the endocrine and metabolic

complications of fungal infections and antifungal therapy, they can more

readily recognize them and favorably affect outcome.

 

Mayo Clin Proc. 2008;83(9):1046-1060

 

http://tinyurl.com/5wxsq6